GlaxoSmithKline (GSK) Reports Q3 EPS of GBP0.32

October 26, 2016 7:10 AM EDT
Get Alerts GSK Hot Sheet
Price: $37.70 +0.72%

Today's EPS Names:
GCO, ALCO, BIG, More
Trade GSK Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

GlaxoSmithKline (NYSE: GSK) reported Q3 EPS of GBP0.32, versus GBP0.23 reported last year. Revenue for the quarter came in at GBP7.54 billion, versus GBP6.13 billion reported last year.

New product sales ¢G1.21 billion +79% (Q1 2016: ¢G821 million; Q2 2016: ¢G1.05 billion) driven by HIV (Tivicay, Triumeq), Respiratory (Relvar/Breo, Anoro, Incruse, Nucala) and Meningitis vaccines (Bexsero, Menveo)

  • New Pharmaceutical product sales represent 25% of total Pharmaceutical sales (Q3 2015: 14%)

Improved operating leverage driven by sales growth, delivery of restructuring and integration benefits and continued tight control of costs including targeted reinvestments

  • Q3 Group core operating profit margin 30.7% (Q3 2015: 28%)
  • Incremental cost savings of ¢G0.2 billion in Q3 2016, with total annual cost savings now at ¢G2.5 billion and on track to deliver target of ¢G3 billion in total

Q3 total earnings per share 16.6p, -1% CER, impacted by charges resulting from increases in valuations of Consumer Healthcare and HIV businesses

Q3 core earnings per share 32p, +12% CER

Continue to expect 2016 core EPS percentage growth to be 11-12% CER

  • If FX rates held at Q3 period end levels, estimated impact of +21% on 2016 Sterling core EPS growth

Q3 net cash inflow from operations of ¢G1.8 billion (Q3 2015: ¢G0.5 billion)

19p dividend declared for Q3. Continue to expect 80p for FY 2016 and 2017

Sustained delivery in R&D pipeline:

  • H2 2016 filings: Shingrix filed in US and on track to be filed in EU in Q4; Closed Triple for COPD on track to be filed in US and EU in Q4; Benlysta subcutaneous for lupus and sirukumab for RA both filed in US and EU
  • Veramyst Rx to OTC switch approved by FDA (expected launch Q1 2017)
  • Phase III trials started for two-drug regimen in HIV (dolutegravir and lamivudine) in Q3; four Phase III trial starts for assets in HIV, respiratory and anaemia expected in Q4
  • Key data points expected on between 20-30 potential assets by end 2018

For earnings history and earnings-related data on GlaxoSmithKline (GSK) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Earnings, Hot Earnings

Related Entities

Earnings

Add Your Comment